Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring-guided adalimumab interval prolongation in rheumatoid arthritis
NL-OMON41716Active, not recruiting
- Sponsor
- Reade, centrum voor Revalidatie en Reumatologie
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab in rheumatoid arthritis (RA), sponsored by Reade, centrum voor Revalidatie en Reumatologie. Primary endpoint: Change in disease activity. Started Nov 2012; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41716.